Medpace Holdings Inc
NASDAQ:MEDP
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
270.58
457.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Medpace Holdings Inc
Medpace Holdings Inc
Revenue
Medpace Holdings Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medpace Holdings Inc
NASDAQ:MEDP
|
Revenue
$2.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Revenue
$42.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Danaher Corp
NYSE:DHR
|
Revenue
$21.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
1%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Revenue
$3.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Revenue
$6.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Revenue
$15.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
11%
|
|
Medpace Holdings Inc
Revenue Breakdown
Breakdown by Geography
Medpace Holdings Inc
Breakdown by Segments
Medpace Holdings Inc
|
Total Revenue:
1.9B
USD
|
|
Revenue Net:
1.9B
USD
|
|
Oncology:
587.1m
USD
|
|
Other:
404.8m
USD
|
|
Metabolic:
376.8m
USD
|
|
Cardiology:
193.7m
USD
|
|
Avai:
163.3m
USD
|
|
Central Nervous System:
160.1m
USD
|
Medpace Holdings Inc
Glance View
Medpace Holdings Inc., a prominent player in the global clinical research organization (CRO) space, has made a name for itself by offering comprehensive drug development services tailored to the needs of pharmaceutical and biotechnology companies. Founded in 1992 and headquartered in Cincinnati, Ohio, the company specializes in conducting clinical trials for innovative therapies across various therapeutic areas, including oncology, cardiology, and infectious diseases. With its unique approach to clinical development, Medpace combines deep operational expertise with a commitment to collaboration and transparency, helping clients navigate the complexities of bringing new drugs to market. The company’s strong track record of successful trial management and regulatory compliance has made it a trusted partner for both established and emerging life sciences firms. As the demand for efficient and effective clinical trials continues to rise in an increasingly competitive market, Medpace is well-positioned for growth. Its focus on ensuring quality and speed enables clients to make faster decisions, which is essential in today's fast-paced healthcare landscape. The company's robust earnings and consistent revenue growth are indicative of its operational excellence and strategic market partnerships. Moreover, with a broad international reach and an experienced workforce, Medpace is adept at adapting to various regulatory environments, further solidifying its reputation as a leader in the CRO industry. For investors, Medpace presents an opportunity to tap into the expanding biopharmaceutical sector, where innovation and patient-centric care are driving demand for clinical development services.
See Also
What is Medpace Holdings Inc's Revenue?
Revenue
2.1B
USD
Based on the financial report for Sep 30, 2024, Medpace Holdings Inc's Revenue amounts to 2.1B USD.
What is Medpace Holdings Inc's Revenue growth rate?
Revenue CAGR 5Y
20%
Over the last year, the Revenue growth was 16%. The average annual Revenue growth rates for Medpace Holdings Inc have been 24% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
